CREXONT's early success was emphasized more strongly, with management citing faster uptake compared to Rytary. Biosimilar investments were highlighted as a key growth driver, whereas prior ...

Crexont prescriptions reached 964 per week by mid-February, capturing 15% of Rytary’s volume and exceeding market expectations. JP Morgan upgraded Amneal to Overweight, raising its price target ...

It raised its sales estimates for the product to $64M for 2025 and $125M for 2026, with peak sales of $300M+, adding it now sees Crexont as "more than replacing Rytary over time." J.P. Morgan said ...

The company aims for 50% formulary coverage for CREXONT in 2025, with a long-term goal to match or surpass Rytary's 70% coverage. Q4 revenues were $731M, representing 18% growth year-over-year ...

As a result, J.P. Morgan is increasing its sales projections, forecasting Crexont revenue of $64 million in 2025, $125 million in 2026, and peak sales above $300 million, surpassing Rytary.

J.P. Morgan analyst Chris Schott reports that Crexont prescriptions are nearing 1,000 per week, with 964 recorded in the week of February 14. The drug is capturing market share faster than expected, ...